The Role of Potassium Binders in Optimal HF Management: Discussing the DIAMOND Study

The Role of Potassium Binders in Optimal HF Management: Discussing the DIAMOND Study

The Role of Potassium Binders in Optimal HF Management: Discussing the DIAMOND Study
RestartResume

Tune in for encouraging results of the DIAMOND trial that may help you manage hyperkalemia while up-titrating RAASi therapy.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    There has been considerable clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. The most recent study is the DIAMOND trial, and results were just presented at the American College of Cardiology 2022 meeting. So what does it mean to “enable” RAASi therapy, and how does this impact outcomes for our patients with heart failure? Join our experts as they discuss the value of these trial results and the body of clinical evidence for use of potassium binders in the management of hyperkalemia in patients with heart failure.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ileana L. Piña, MD, MPH, FAHA, FACC
    Clinical Professor of Medicine
    College of Medicine
    Central Michigan University
    Mount Pleasant, MI 

    Consulting Fees: Novartis, Relypsa

    Faculty:
    Stefan D. Anker, MD, PhD

    Division of Cardiology & Metabolism: Heart Failure, Cachexia and Sarcopenia
    Department of Cardiology & BCRT
    Berlin, Germany

    Consulting Fees: AstraZeneca, Bayer, BI, Brahms, Novartis, Servier, Vifor Pharma

    Javed Butler, MD, MBA, MPH
    President, Baylor Scott and White Research Institute
    Dallas, TX
    Distinguished Professor of Medicine, University of Mississippi Medical Center
    Jackson, MS

    Consulting Fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Ltd., Vifor Pharma

    Bertram Pitt, MD
    Professor of Medicine, Emeritus
    University of Michigan School of Medicine
    Ann Arbor, MI

    Consulting Fees/Honoraria: Bayer, Tricida, AstraZeneca, Boehringer Ingelheim Pharmaceutical, Inc, Merck & Co., Inc., scPharmaceuticals, KBP Biosciences, Johnson & Johnson, Novartis, Relypsa, Inc, a Vifor Pharma Group Company.
    Ownership/Partnership/Principal: scPharmaceuticals, Tricida, KBP Biosciences

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • James Seternus, DO, has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the challenges in managing medical therapy in patients with HFrEF experiencing recurrent hyperkalemia
    • Discuss clinical considerations for patients with HFrEF and comorbid conditions like diabetes and kidney dysfunction
    • Evaluate clinical trial data concerning the use of potassium binders in enabling optimal dosing of RAASi therapy in patients with HFrEF
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, primary care physicians, and all other professionals involved in the identification and treatment of HF.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this Podcast PLUS activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free